To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Evotec Receives Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim
Evotec AG has announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of EUR 2.5 million to Evotec.
The milestone was for the transition of an oncology programme into pre-clinical profiling.
Dr Mario Polywka, Chief Operating Officer of Evotec commented: “This is the seventeenth milestone achieved as part of our alliance with Boehringer Ingelheim and represents an important transition of a compound into pre-clinical profiling. We are pleased the collaborative efforts of teams from Evotec and Boehringer Ingelheim continue to show success in progressing compounds towards the clinic.”
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
